文献速递MDS 与骨髓增殖性肿瘤

Ropeginterferon alfa-2b对比标准治疗真性红细胞增多症:PROUD-PV与CONTINUATION-PV随机非劣效3期试验及扩展研究

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
PubMed 文献 · Lancet Haematol · 2020-01-31

PROUD-PV及扩展研究CONTINUATION-PV比较ropeginterferon alfa-2b与羟基脲治疗早期真性红细胞增多症。12个月时主要终点未达非劣效,但36个月时ropeginterferon组疾病负担改善的完全血液学缓解率优于羟基脲组,且耐受性良好。

要点

  • 12个月完全血液学缓解伴正常脾脏比例两组无显著差异,非劣效未成立。
  • 36个月时ropeginterferon组完全血液学缓解伴疾病负担改善比例显著优于羟基脲。
  • ropeginterferon组常见3-4级不良事件为γ-谷氨酰转移酶和丙氨酸氨基转移酶升高。

核心结论

  • 在主要为无脾肿大的早期真性红细胞增多症患者中,ropeginterferon alfa-2b能有效诱导血液学缓解,但12个月时在血液学缓解伴正常脾脏大小方面未证明非劣效于羟基脲。
  • ropeginterferon alfa-2b的缓解随时间持续增加,36个月时优于羟基脲,具有良好的耐受性,提供了一种有价值的长期治疗选择。

研究设计与样本

  • PROUD-PV及其扩展研究CONTINUATION-PV为3期、随机、对照、开放标签试验,在欧洲48家诊所进行。
  • 纳入18岁及以上早期真性红细胞增多症患者(无细胞减灭治疗史或既往羟基脲治疗少于3年),按WHO 2008标准诊断。
  • 患者1:1随机分配至ropeginterferon alfa-2b(皮下注射,每2周一次,起始100 μg)或羟基脲(口服,起始500 mg/天)。
  • 共257例患者随机分配,每组治疗127例(羟基脲组3例撤回知情同意),171例转入CONTINUATION-PV。
  • 疗效和安全性分析采用符合方案集。

主要发现

  • PROUD-PV中,12个月时达到完全血液学缓解伴正常脾脏的复合主要终点:ropeginterferon组26/122例(21%),标准治疗组34/123例(28%)。
  • 最常见3-4级治疗相关不良事件:ropeginterferon组为γ-谷氨酰转移酶升高(7/127例,6%)和丙氨酸氨基转移酶升高(4/127例,3%);标准治疗组为白细胞减少(6/127例,5%)和血小板减少(5/127例,4%)。

关键数值与推荐

  • 完全血液学缓解伴正常脾脏大小定义:脾脏纵向直径女性≤12 cm、男性≤13 cm。
  • PROUD-PV主要终点为12个月时完全血液学缓解伴正常脾脏大小的非劣效性。
  • CONTINUATION-PV共同主要终点为完全血液学缓解伴脾脏大小正常化以及伴疾病负担改善(即脾肿大、微血管障碍、瘙痒和头痛)。

临床怎么用

  • 对于早期真性红细胞增多症患者,ropeginterferon alfa-2b是可考虑的长期治疗选择,尤其关注36个月时疾病负担改善的获益。
  • 治疗期间需监测肝功能(γ-谷氨酰转移酶和丙氨酸氨基转移酶),以及时发现3-4级不良事件。
  • 12个月时若以完全血液学缓解伴正常脾脏大小为决策节点,ropeginterferon alfa-2b未证明非劣效于羟基脲,需结合个体情况选择。

局限性

  • 开放标签设计可能引入偏倚。
  • CONTINUATION-PV为中期分析(36个月),研究仍在进行中。
  • 入组患者主要为早期且无脾肿大,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PROUD-PV and CONTINUATION-PV trials aimed to compare the novel monopegylated interferon ropeginterferon alfa-2b with hydroxyurea, the standard therapy for patients with polycythaemia vera, over 3 years of treatment. METHODS: PROUD-PV and its extension study, CONTINUATION-PV, were phase 3, randomised, controlled, open-label, trials done in 48 clinics in Europe. Patients were eligible if 18 years or older with early stage polycythaemia vera (no history of cytoreductive treatment or less than 3 years of previous hydroxyurea treatment) diagnosed by WHO's 2008 criteria. Patients were randomly assigned 1:1 to ropeginterferon alfa-2b (subcutaneously every 2 weeks, starting at 100 μg) or hydroxyurea (orally starting at 500 mg/day). After 1 year, patients could opt to enter the extension part of the trial, CONTINUATION-PV. The primary endpoint in PROUD-PV was non-inferiority of ropeginterferon alfa-2b versus hydroxyurea regarding complete haematological response with normal spleen size (longitudinal diameter of ≤12 cm for women and ≤13 cm for men) at 12 months; in CONTINUATION-PV, the coprimary endpoints were complete haematological response with normalisation of spleen size and with improved disease burden (ie, splenomegaly, microvascular disturbances, pruritus, and headache). We present the final results of PROUD-PV and an interim analysis at 36 months of the CONTINUATION-PV study (per statistical analysis plan). Analyses for safety and efficacy were per-protocol. The trials were registered on EudraCT, 2012-005259-18 (PROUD-PV) and 2014-001357-17 (CONTINUATION-PV, which is ongoing). FINDINGS: Patients were recruited from Sept 17, 2013 to March 13, 2015 with 306 enrolled. 257 patients were randomly assigned, 127 were treated in each group (three patients withdrew consent in the hydroxyurea group), and 171 rolled over to the CONTINUATION-PV trial. Median follow-up was 182·1 weeks (IQR 166·3-201·7) in the ropeginterferon alfa-2b and 164·5 weeks (144·4-169·3) in the standard therapy group. In PROUD-PV, 26 (21%) of 122 patients in the ropeginterferon alfa-2b group and 34 (28%) of 123 patients in the standard therapy group met the composite primary endpoint of complete haematological response with normal spleen size. In CONTINUATION-PV, complete haematological response with improved disease burden was met in 50 (53%) of 95 patients in the ropeginterferon alfa-2b group versus 28 (38%) of 74 patients in the hydroxyurea group, p=0·044 at 36 months. Complete haematological response without the spleen criterion in the ropeginterferon alfa-2b group versus standard therapy group were: 53 (43%) of 123 patients versus 57 (46%) of 125 patients, p=0·63 at 12 months (PROUD-PV), and 67 (71%) of 95 patients versus 38 (51%) of 74 patients, p=0·012 at 36 months (CONTINUATION-PV). The most frequently reported grade 3 and grade 4 treatment-related adverse events were increased γ-glutamyltransferase (seven [6%] of 127 patients) and increased alanine aminotransferase (four [3%] of 127 patients) in the ropeginterferon alfa-2b group, and leucopenia (six [5%] of 127 patients) and thrombocytopenia (five [4%] of 127 patients) in the standard therapy group. Treatment-related serious adverse events occurred in three (2%) of 127 patients in the ropeginterferon alfa-2b group and five (4%) of 127 patients in the hydroxyurea group. One treatment-related death was reported in the standard therapy group (acute leukaemia). INTERPRETATION: In patients with early polycythaemia vera, who predominantly presented without splenomegaly, ropeginterferon alfa-2b was effective in inducing haematological responses; non-inferiority to hydroxyurea regarding haematological response and normal spleen size was not shown at 12 months. However, response to ropeginterferon alfa-2b continued to increase over time with improved responses compared with hydroxyurea at 36 months. Considering the high and durable haematological and molecular responses and its good tolerability, ropeginterferon alfa-2b offers a valuable and safe long-term treatment option with features distinct from hydroxyurea. FUNDING: AOP Orphan Pharmaceuticals AG.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020. PMID: 32014125. doi:10.1016/S2352-3026(19)30236-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。